Polyunsaturated Fatty Acids-based Bars Effect on Metabolic Syndrome Patients

NCT07627555 | Completed DMC

• 1 other identifier: IRB-UOL-FAHS/570/2025
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to manage dyslipidemia through Polyunsaturated fatty acids based bar among patients with metabolic syndrome.

Conditions

Dyslipidemia; Metabolic Syndrome (MetS)

Keywords

lipid profile; omega 3 fatty acids; metabolic syndrome; cardiovascular diseases; poly unsaturated fatty acids

Outcome Measures

Primary Outcomes (2)

• Body Mass Index

  BMI is defined as body weight in kilograms divided by height in meters squared (kg/m²). BMI cut-off points are used to assess weight status, categorizing individuals as underweight, normal, overweight or obese. Obesity is further classified into grades 1, 2 and 3.

  60 days

• Lipid Profile

  Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides levels were measured.

  60 days

Study Arms (2)

Control group T0

PLACEBO COMPARATOR

participants have taken one jelly candy as a mid-morning snack for a duration of 2 months.

Dietary Supplement: Jelly Candy

Experimental group T1

EXPERIMENTAL

participants have taken one PUFA bar as a mid- morning snack for a duration of 2 months.

Dietary Supplement: PUFA Bar

Interventions

Jelly Candy DIETARY_SUPPLEMENT

participants were advised to take one jelly candy as a mid-morning snack for a duration of 2 months.

Control group T0

PUFA Bar DIETARY_SUPPLEMENT

Participants were advised to taken one PUFA bar as a mid- morning snack for a duration of 2 months.

Experimental group T1

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Metabolic syndrome patient's age 40 to 65 years with BMI (above 25 kg/m 2 ) was major part of this study.
• Patients having Triglyceride levels range from mild to moderate (150 to 499 mg/dL) are included in the study.
• Patients having LDL (Low density lipoprotein) range from mild (130-159 mg/dL) to moderate (160-189 mg/dL) are included in the study.
• Patients having HDL (High-density lipoprotein) range from mild to moderate (60 mg/dL or higher) have been included in the study.

You may not qualify if:

• Lactating and pregnant women will not be included.
• Patients who are using any kind of medicine.
• Any person allergic to nuts.
• Adults suffering from critical health conditions, including cancer.

Sponsors & Collaborators

• University of Lahore: lead

Study Sites (1)

University of Lahore

Lahore, Pakistan

Location

Related Links

• Related Info
• Related Info

MeSH Terms

Conditions

Dyslipidemias; Metabolic Syndrome; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Head University Institute of Diet and Nutritional Sciences

Study Record Dates

• First Submitted: May 30, 2026
• First Posted: June 4, 2026
• Study Start: February 6, 2025
• Primary Completion: May 15, 2025
• Study Completion: July 16, 2025
• Last Updated: June 4, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share

Locations

PA (1)